THQ - abrdn Healthcare Opportunities Fund
A closed-end fund run by abrdn. Invests in healthcare companies. Listed on the New York Stock Exchange.
Is anyone targeting this fund?
No - nobody has reported owning 5% or more of this fund.
Is the fund doing anything you need to act on?
Nothing right now.
What this means for you
No investor has reported owning 5% or more of this fund. That is the normal state for most closed-end funds.
Nothing is required of you. If that changes, the notice appears here within a day of being filed with the regulator.
What happened, and when
Nothing on file yet. No large investor has reported a stake in this fund, and the fund has not announced a buy-back, a vote or a closing.
About this fund
- Run by abrdn Inc. As of Sept 30, 2025, from the fund's yearly report. Original document →
- Size: about $826 million of holdings, as of June 30, 2026. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
- Borrowing: the fund borrows about 22% on top of its own money, as of June 30, 2026. Borrowed money makes gains and losses bigger. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
- Costs: 1.3% a year in management fees; 3% a year in total, including interest on borrowed money. Fiscal year ended Sept 30, 2025. As of Sept 30, 2025, from the fund's yearly report. Original document →
- Payouts: last fiscal year (ended Sept 30, 2025) the fund paid $2.16 a share. $0.10 of that was income; $2.06 was your own money back, not income. As of Sept 30, 2025, from the fund's annual report. Original document →
- Value of holdings per share at the last fiscal year end (Sept 30, 2025): $17.89. The shares traded at $17.29, about 3.4% below that. As of Sept 30, 2025, from the fund's yearly report. Original document →
- How the holdings did: up 14.8% over the last three months we have (April-June 2026), before the share price is taken into account. Over the last 12 months: +14.8%. As of June 30, 2026, from the fund's quarterly holdings report. Original document →
- How the holdings did over the fiscal year (ended Sept 30, 2025): the value of the holdings returned -12.2%. How the share price did: the shares returned -12.3% over the same year, counting payouts and the change in the market price. As of Sept 30, 2025, from the fund's annual report. Original document →
- First reported to the regulator in 2014.
What the fund holds
Mostly shares (83%), the rest bonds, preferred shares and cash and short-term holdings. About 90% issued in the U.S.
The fund also sells options on its holdings to raise income.
- UnitedHealth Group - 6.1%
- VeraDermics - 5.3%
- Abbott Laboratories - 4.8%
- Merck & - 4.4%
- Medtronic PLC - 4.3%
- Thermo Fisher Scientific - 4.2%
- Veradermics, Inc. - 4.1%
- Intuitive Surgical - 3.4%
- CVS Health - 3.3%
- Danaher - 3.2%
Show all 25
- Oruka Therapeutics - 2.9%
- uniQure NV - 2.8%
- Humana - 2.8%
- Elevance Health - 2.6%
- BioCryst Pharmaceuticals - 2.5%
- AbbVie - 2.5%
- Boston Scientific - 2.4%
- Sarepta Therapeutics - 2%
- NeoGenomics - 1.9%
- Insulet - 1.9%
- Cash and short-term - 1.9%
- Praxis Precision Medicines - 1.8%
- ARS Pharmaceuticals - 1.8%
- Abivax SA - 1.7%
- Alignment Healthcare - 1.7%
As of June 30, 2026, from the fund's quarterly holdings report. Original document →
Details: all notices, events and fund facts
No notices from large investors on file.
No announcements from the fund on file.
- Run by
- abrdn Inc.
- Fund family
- ABERDEENCF
- Exchange
- New York Stock Exchange
- Regulator's file number
- 811-22955
- Auditor
- KPMG LLP
- Fiscal year end
- Sept 30, 2025
- Number of holdings
- 110
- Preferred share classes
- none
Email me when something new is filed for THQ
Free. One email per notice or announcement, usually within a day. No password.